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Background: The formulation of docetaxel available for clinical use (Taxotere®) contains 
a high concentration of polysorbate 80 (Tween 80). After incorporation of Tween 80 into 
poly-ε-caprolactone (PCL)-Tween 80 copolymer, the relative amount of Tween 80 should be 
decreased and the advantages of PCL and Tween 80 should be combined.
Methods: A novel PCL-Tween 80 copolymer was synthesized from ε-caprolactone and 
Tween 80 in the presence of stannous octoate as a catalyst via ring opening polymerization. 
Two types of nanoparticle formulation were made from commercial PCL and a self-synthesized 
PCL-Tween 80 copolymer using a modified solvent extraction/evaporation method.
Results: The nanoparticles were found by field emission scanning electron microscopy to have 
a spherical shape and be 200 nm in diameter. The copolymers could encapsulate 10% of the drug 
in the nanoparticles and release 34.9% of the encapsulated drug over 28 days. PCL-Tween 80 
nanoparticles could be internalized into the cells and had higher cellular uptake than the PCL 
nanoparticles. The drug-loaded PCL-Tween 80 nanoparticles showed better in vitro cytotoxicity 
towards C6 cancer cells than commercial Taxotere at the same drug concentration.
Conclusion: Nanoparticles using PCL-Tween 80 copolymer as drug delivery vehicles may 
have a promising outcome for cancer patients.
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Introduction
Cancer remains a major health problem worldwide. The use of polymeric nano-
particles as drug delivery vehicles for anticancer therapeutics has great potential to 
revolutionize the future of cancer therapy. However, nanoparticles can be rapidly 
eliminated/excreted by macrophages in the reticuloendothelial system located pri-
marily in the liver and spleen, resulting in a short half-life in the circulation after 
intravenous administration.1 Various attempts have been made to achieve a longer 
circulation time to avoid or reduce the absorption of nanoparticles onto phagocytes.2 
Previous studies have shown that nanoparticles coated with a neutral hydrophilic 
outer layer can generate stealth particles and decrease phagocytic uptake, and thus 
significantly increase the blood circulation time with a high level of drug concentration 
in nonreticuloendothelial organs, such as the intestines and kidney.3,4 A number of 
surfactants, such as poloxamines,4 poloxamers, D-α-tocopheryl polyethylene glycol 
1000 succinate (TPGS),5 polyethylene glycol,6 and Tween 804,7 have been used as coat-
ing materials. Importantly, some coating surfactants may help nanoparticles cross the 
gastrointestinal and blood-brain barriers.8,9 Systemically administered chemotherapy 
is often ineffective in the treatment of central nervous system diseases. One reason 
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for this low efficacy is insufficient drug delivery to the 
brain due to the presence of the blood–brain barrier, which 
restricts exchange of solutes between the blood and extracel-
lular brain fluid. Tween 80-coated nanoparticles have been 
reported to have the ability to transport loaded drugs across 
the blood–brain barrier after intravenous injection.8–10 It has 
been reported that polybutylcyanoacrylate nanoparticles are 
able to deliver hexapeptide dalargin, doxorubicin, and other 
agents which are significantly obstructed by the blood–brain 
barrier.11 This may be because the nanoparticles can adsorb 
apoliproprotein E, which mimics low-density lipoprotein, 
onto the nanoparticle surface and thus be uptaken via 
receptor-mediated endocytosis by endothelial cells in the 
brain capillaries.12–15 It was reported that Tween 80-coated 
polybutylcyanoacrylate nanoparticles could enhance brain 
concentrations of administered doxorubicin by about 60-fold 
in mice.16 Tween 80 is a polyethylene sorbitol ester, with 
a calculated molecular weight of 1310 Da, assuming 20 
ethylene oxide units, one sorbitol, and one oleic acid as the 
primary fatty acid. Tween 80 is widely used in biochemical 
applications, including for solubilizing proteins, isolating 
nuclei from cells in cell culture, growing tubercle bacilli, 
and emulsifying and dispersing substances in medicinal and 
food products.17
Docetaxel is one of the most potent anticancer agents, 
and has activity against a wide range of tumors. Its com-
mercial formulation, Taxotere®, is formulated with a high 
concentration of Tween 80 (40 g/L), which has been found 
to have severe side effects, including hypersensitivity 
reactions, cumulative fluid retention, nausea, mouth sores, 
fatigue, hair loss, peripheral neuropathy, and anemia, and 
has shown incompatibility with commonly used   polyvinyl 
chloride intravenous administration sets.18 Therefore, 
investigation of alternative formulations of docetaxel 
without Tween 80 or with addition of a low concentration 
of Tween 80 is under way, and several approaches based 
on docetaxel conjugation,19 nanoparticles,20 liposomes,21 
polymeric nanoparticles,22 micelles,23 and prodrugs24 have 
been proposed. In addition, poly-ε-caprolactone (PCL) is 
a very attractive synthetic polymer due to its properties of 
high permeability, lack of toxicity, and biodegradability.25 
In this research, we developed PCL-Tween 80 as a novel 
copolymer and a novel PCL-Tween 80 nanoparticle as a 
potential drug carrier for cancer chemotherapy. Using this 
design, the relative amount of Tween 80 would be decreased 
and the advantages of PCL and Tween 80 would be combined 
after the incorporation of Tween 80 into a PCL-Tween 80 
copolymer.
Materials and methods
Materials
PCL (molecular weight 42,000 Da), stannous octoate 
[Sn(OOCC7H15)2], and Tween 80 were supplied by 
  Sigma-Aldrich (St Louis, MO). The monomer, ε-caprolactone, 
was purchased from Acros Organics (Geel, Belgium). 
TPGS [C33O5H54(CH2CH2O)23] was from Pubmed Co, Ltd, 
  (Shenzhen, China). Docetaxel of purity 99.8% was purchased 
from Pubmed. Fetal bovine serum was obtained from Gibco 
(Life Technologies, AG, Switzerland). Acetonitrile and 
methanol were purchased from EM Science (ChromAR, 
high-pressure liquid chromatography grade, Mallinckrodt 
Baker, Phillipsburg, NJ). All other chemicals used were of 
the highest quality commercially available. Ultrapure water 
produced by Boon Environmental Industry Co, Ltd, (Tianjin, 
China) was used throughout all the experiments.
Synthesis of PCL-Tween 80 copolymer
As shown in Figure 1, PCL-Tween 80 copolymer was 
  synthesized from ε-caprolactone and Tween 80 in the 
  presence of stannous octoate as a catalyst via ring   opening 
polymerization. Briefly, 9 g of ε-caprolactone, 1 g of 
Tween 80, and 0.02 mL of stannous octoate were added to a 
flask. The mixture was heated to 160°C and allowed to react 
for 12 hours. Synthesis was carried out in an oxygen-free 
and moisture-free environment. The product was dissolved 
in dichloromethane and then precipitated in excess cold 
methanol to remove unreacted ε-caprolactone monomers 
and Tween 80. The final product was collected by filtration 
and vacuum-dried at 45°C for two days.
Characterization of PCL-Tween 80 
copolymer
A Fourier transform infrared spectrophotometer (Thermo 
Nicolet, Madison, WI) was used to investigate the   molecular 
structure of the PCL-Tween 80 copolymer. Briefly, samples for 
Fourier transform infrared analysis were prepared by grinding 
99% KBr with 1% copolymer and then pressing the mixture 
into a transparent tablet. The Tween 80 content and number-
averaged molecular weight of the   copolymer were determined 
by 1H nuclear magnetic resonance (NMR) in CDCl3 at 300 Hz 
(Bruker ACF300). The weight-  averaged molecular weight 
and molecular weight   distribution were determined by gel 
permeation chromatography.   Thermogravimetric analysis 
(TGA 2050 thermogravimetric analyzer, Perkin Elmer, 
Waltham, MA) was carried out to investigate the thermal 
properties of the copolymer. During   thermogravimetric 
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analysis, about 5–15 mg of the copolymer sample was heated 
from 0°C to 600°C at a rate of 10°C/minute. The weight loss 
pattern in the copolymer thermogram could be related to the 
composition of the copolymer.
Preparation of docetaxel-loaded 
nanoparticles
The nanoparticles were prepared by a solvent extraction/
evaporation method with slight modification.18 Briefly, with a 
theoretical loading of 10%, 11.1 mg of docetaxel and 100 mg 
PCL-Tween 80 copolymer were dissolved in 8 mL dichlo-
romethane to prepare the nanoparticles. The solution formed 
was poured into 120 mL of 0.03% (w/v) TPGS solution under 
gentle stirring. The mixture was sonicated for 120 seconds at 
25 W output to form an oil/water emulsion. The emulsion was 
then evaporated overnight under reduced pressure to remove 
the dichloromethane. The particle suspension was centrifuged 
at 23,000 rpm for 15 minutes and then washed three times 
to remove the emulsifier and unencapsulated drug. The 
resulting particles were resuspended in 10 mL of deionized 
water and freeze-dried. The fluorescent coumarin 6-loaded 
PCL-Tween 80 nanoparticles were prepared in the same 
way, except that 0.1% (w/v) coumarin 6 was encapsulated 
instead of docetaxel. Docetaxel-loaded PCL nanoparticles 
were prepared by the same procedure.
Nanoparticle characterization
Particle size and zeta potential
The particle size and size distribution of the nanoparticles 
were measured by dynamic light scattering (Zetasizer Nano 
ZS90, Malvern Instruments Ltd, Worcestershire, UK). The 
dried particles (about 2 mg) were suspended in deionized 
water before measurement. The zeta potential of the nano-
particles was determined by laser Doppler anemometry 
(Zetasizer Nano ZS90). The measurement was performed 
in triplicate.
Surface morphology
The surface morphology of the nanoparticles was observed 
by field emission scanning electron microscopy using a 
JEOL JSM-6700F system (JEOL, Tokyo, Japan) operated at 
a 5.0 kV accelerating voltage. To prepare samples for field 
emission scanning electron microscopy, a drop of the particle 
suspension was placed on a grid or stud, and the superna-
tant liquid was removed with a capillary after the particles 
were allowed to settle. The particles were then coated with 
a platinum layer using a JFC-1300 automatic fine platinum 
coater (JEOL) for 30 seconds.
Drug content and encapsulation efficiency
Drug loading content and encapsulation efficiency of the 
nanoparticles were determined by high-pressure liquid 
  chromatography (LC 1200, Agilent Technologies, Santa 
Clara, CA) as described previously.25 In short, 5 mg of the 
nanoparticles were dissolved in 1 mL dichloromethane 
under   vigorous vortexing. The organic solution was trans-
ferred to 5 mL of mobile phase consisting of deionized 
water and acetonitrile (50:50, v/v). A nitrogen stream was 
introduced to evaporate the dichloromethane for about 
15 minutes, and then a clear solution was obtained for high-
pressure liquid chromatographic analysis. A reverse-phase 
Inertsil® C-18 column (150 mm × 4.6 mm, pore size 5 mm, 
GL Science Inc, Tokyo, Japan) was used. The flow rate of 
the mobile phase was 1 mL/minute. The column effluent 
was detected at 227 nm with an ultraviolet-visible detector.   
The drug encapsulation efficiency was defined as the ratio 
between the amount of docetaxel encapsulated in the nano-
particles and that added in the process. Experiments were 
performed in triplicate, and results are expressed as the 
mean ± standard deviation.
In vitro release studies
In this assay, 15 mg aliquots of drug-loaded nanoparticles, 
weighed by an electronic balance (XS105DU, Mettler 
Toledo, Greifensee, Switzerland), were dispersed in 5 mL 
of release medium (phosphate buffer solution, pH 7.4, con-
taining 0.05% w/v Tween 80) to form a suspension. Tween 
80 was used to increase the solubility of docetaxel in the 
buffer solution and avoid binding of docetaxel to the tube 
wall. The suspension was transferred into a regenerated cel-
lulose dialysis membrane (Spectra/Por 6, molecular weight 
cutoff 1000, Spectrum, Houston, TX). The closed bag was 
then put into a centrifuge tube and immersed in 15 mL of 
release medium. The tube was put in an orbital water bath 
shaking at 120 rpm and at 37°C; 10 mL aliquots of solutions 
were periodically removed for analysis and replaced with 
fresh medium. The collected samples were extracted with 
2 mL dichloromethane and reconstituted in a 5 mL mobile 
phase. A nitrogen stream was introduced to evaporate the 
  dichloromethane. The analysis procedure was the same as 
for the measurement of drug encapsulation efficiency.
In vitro cell test
Cell culture
Glioma C6 cell lines were obtained from the American 
Tissue Culture Collection (Rockville, MD) and cultured 
using the methods described by Freshney.26 Briefly, cells 
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(104 cells/mL) were seeded in 75 cm2 tissue culture flasks 
(15 mL/flask) with Dulbecco’s modified Eagle medium 
supplemented with 10% fetal bovine serum and 1% antibi-
otic, and incubated at 37°C in a humidified environment of 
5% CO2.
Cellular uptake assay
The cell lines used in the study were cultured in a 96-well 
black bottom plate at a density of 5 × 103 cells/well for 
24 hours, before addition of medium containing fluorescent 
nanoparticles at a series of concentrations, ie, 100, 200, and 
500 µg/mL, and incubation for another 2 hours. The cells 
were then washed three times with phosphate-buffered solu-
tion before dissolving in 0.5% Triton-X 100 NaOH aqueous 
solution (0.2 N). Particle uptake by the cell monolayers was 
then determined by measuring the fluorescent intensity with 
a microplate reader. The fluorescent intensity of the cou-
marin 6-loaded nanoparticles was determined in a similar 
manner prior to the experiment. The results obtained were 
expressed as a percentage of the total number of coumarin 
6-loaded nanoparticles found in the solubilized cells to the 
total number of coumarin 6-loaded nanoparticles applied to 
the cells.
For analysis using confocal laser scanning microscopy 
(Olympus Fluoview FV-1000, Olympus Optical Co, Ltd, 
Tokyo, Japan), the cells were first cultured on Lab-Tek™ 
chambered coverglass for 24 hours (104 cells/chamber). The 
cell monolayers were then incubated with medium containing 
PCL-Tween 80 nanoparticles (200 µg/mL) for 2 hours and 
rinsed three times with phosphate-buffered solution. After 
fixing with ethanol for 20 minutes, they were washed again 
with phosphate-buffered solution, and stained thereafter 
with 4′,6-diamidino-2-phenylindole dihydrochloride (DAPI, 
Fluka, Buche, Switzerland) for 30 minutes and rinsed again 
to remove the free dye. The cells were then viewed and 
imaged by confocal laser scanning microscopy with imag-
ing software. Images of the cells were determined with a 
differential interference contrast channel, and the images 
of coumarin 6-loaded nanoparticles and the nuclei of cells 
stained by DAPI were recorded using a blue channel (DAPI) 
with excitation at 340 nm and a green channel (coumarin 6) 
with excitation at 488 nm.
Cell viability assay
In this study, in vitro cancer cell viability was assessed using 
an MTT toxic assay, which is widely used to evaluate the 
cytotoxic activity of drugs or biomaterials. This method is 
based on the capacity of living cells to metabolize the yellow 
tetrazolium salt, MTT, to a chromophore formazan product, 
the absorbance of which can be determined by spectrophoto-
metric measurement. C6 glioma cells (passages 6–10) were 
used for in vitro evaluation of the cytotoxicity of docetaxel-
loaded PCL-Tween 80 nanoparticles in comparison with 
docetaxel formulated in Tween 80 (Taxotere) and docetaxel-
loaded PCL nanoparticles. The cells were cultured in 20 mL 
of Dulbecco’s modified Eagle medium supplemented with 
10% fetal bovine serum and 1% antibiotic-antimycotic in 
a 75 cm2 culture flask. The culture flask was incubated at 
37°C in a humidified environment containing 5% CO2. 
The medium was replenished every other day until conflu-
ency was reached. The cells were harvested with 0.125% 
of trypsin-ethylenediamine tetra-acetic acid solution and 
seeded in 96-well transparent plates (Costar, Corning, NY) 
at 4 × 104 cells/well.
When the cells seeded in the 96-well transparent plates 
are at about 70% confluence, the culture medium in the wells 
was replaced with 100 µL of the drug-loaded nanoparticle 
suspension or Taxotere in fresh medium, with drug concen-
trations ranging from 0.25 to 25 µg/mL for 24 and 72 hours 
of incubation. The drug-loaded nanoparticles were sterilized 
by gamma irradiation before the cytotoxicity test. Six wells 
were used for each nanoparticle sample. One row of 12 wells 
was used as a positive control, in which only culture medium 
was added to the wells. At the designated times, medium 
containing the drug was removed and the cells were washed 
twice with 50 µL of phosphate-buffered solution, after which 
90 µL of culture medium and 10 µL of MTT were added to 
each of the wells. The cells were incubated for 3–4 hours and 
the solution was then removed from the precipitate. A total of 
100 mL of 2-propanol was added to the wells and the level 
of absorbance was measured using a microplate reader. 
Untreated cells were used as a control with 100% viability, 
and cells without addition of MTT were used as a blank to 
calibrate the spectrophotometer to zero absorbance.
Statistical analyses
The data were expressed as the mean ± standard   deviation. 
The significance of differences was assessed using the 
  Student’s t-test, with P , 0.05 considered to indicate a 
statistically significant difference.
Results and discussion
Characterization of PCL-Tween 80 
copolymer
As shown in Figure 1, PCL-Tween 80 copolymers 
were synthesized by ring opening polymerization in the 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2682
Ma et alInternational Journal of Nanomedicine 2011:6
  presence of ε-caprolactone and Tween 80. The PCL-
Tween 80 copolymer was then characterized by 1H NMR 
in CDCl3, and the spectrum is shown in Figure 2. The peak 
at 3.65 ppm could be attributed to the –CH2 protons of the 
polyethylene oxide part of Tween 80 in the copolymers. 
The small peaks in the aliphatic region belong to various 
moieties of –CH3 and –CH2 protons in the Tween 80 tails. 
The peaks at 4.06 (peak A), 2.31 (peak C), 1.60–1.70 
(peak D), and 1.35–1.43 (peak E) were assigned to –OCH2, 
–COCH2, –CH2(4 H) and –CH2(2 H) segments of PCL, 
respectively.25
Figure 3 shows the Fourier transform infrared spectra of 
the PCL-Tween 80 copolymer. In the PCL-Tween 80 spec-
trum, the carbonyl band of PCL-Tween 80 copolymer appears 
at 1729 cm−1. The bands in the range 2867–2950 cm−1 are 
assigned to the –CH2 stretching band of PCL. The absorption 
band at 3400–3650 cm−1 is attributed to the terminal hydroxyl 
group and that at 1044–1298 cm−1 is due to C–O stretching.27 
Of these, the band at 1243 cm−1 is assigned to asymmetric 
COC stretching.28 The band at 1298 cm−1 has been used in the 
literature to investigate the crystallinity change in PCL.29 The 
results confirmed the successful synthesis of PCL-Tween 80 
copolymer.
In the gel permeation chromatography analysis, we con-
firmed that the PCL-Tween 80 copolymer was   synthesized 
by ring-opening polymerization. The product was not a 
physical mixture of Tween 80 and ε-caprolactone. The 
number-averaged molecular weight calculated from the 
gel permeation chromatograph was 21,656. The   molecular 
weight of the PCL-Tween 80 copolymer could also be 
calculated using the ratio between the NMR peak areas at 
1.35–1.43 (peak area 1.07) and 3.65 (peak area 0.23). The 
number-averaged molecular weight of the PCL-Tween 80 
copolymer was determined to be 18,388. It seems that the 
molecular weight detected by gel permeation chromatogra-
phy and NMR were the same. In addition, the feeding ratio of 
ε-caprolactone and the Tween 80 molecular mass were 90% 
and 10%, respectively. However, the ratio of ε-caprolactone 
and Tween 80 molecular mass integrated into the PCL-
Tween 80 copolymer was 92.88% and 7.12%.
Thermogravimetric analysis was performed on the 
  synthesized copolymers to investigate their thermal 
  properties. Figure 4 shows typical thermal degradation 
profiles for PCL-Tween 80 copolymer, which have two 
main regions of weight loss. Each turning point marked 
the combustion of a new component in the copolymers. 
The 200°C–420°C and 420°C–550°C combustion zones were 
attributed to the PCL and Tween 80 parts of the copolymers, 
respectively. These results further confirmed successful 
synthesis of PCL-Tween 80 copolymer.
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Figure  1  Schematic  diagram  of  the  synthesis  of  PCL-Tween  80  copolymer. 
Abbreviation: PCL, poly-ε-caprolactone.
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Figure 2 Typical 1H-NMR spectra of PCL-Tween 80 copolymer.
Abbreviations: PCL, poly-ε-caprolactone; NMR, nuclear magnetic resonance.
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Figure  3  Fourier  transform  infrared  spectra  of  PCL-Tween  80  copolymer. 
Abbreviation: PCL, poly-ε-caprolactone.
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Characterization of drug-loaded 
nanoparticles
Size, zeta potential, and encapsulation efficiency
The particle size data for the docetaxel-loaded PCL-Tween 80 
nanoparticles, drug-free PCL-Tween 80 nanoparticles, and 
docetaxel-loaded PCL nanoparticles fabricated in this study 
are shown in Table 1. Physicochemical characteristics, such 
as particle size and surface properties, play key roles in 
determining their in vitro drug release, cellular uptake, and 
cytotoxicity of these nanoparticles, as well as their in vivo 
pharmacokinetics and biodistribution, and thereby the thera-
peutic efficacy of the encapsulated drug.30–32 Permeability 
of the particles through the intestinal mucosa decreases 
with increasing particle size, reaching a cutoff at around 
500 nm.31 The resulting nanoparticles were 200–280 nm in 
diameter, which is in the size range favoring cellular uptake 
of nanoparticles.32 The average size of the PCL-Tween 
80 nanoparticles was much smaller and the size distribu-
tion much narrower than that of the PCL nanoparticles. 
This may be due to the self-emulsifying function of the 
Tween 80 component in the copolymer. There was also 
evidence that the amphipathic Tween 80 surfactants align 
themselves at the oil-water interface to promote stability 
of the particles by lowering the surface energy and thus 
resisting particle coalescence and flocculation.25,32 It can be 
also seen from Table 1 that the PCL-Tween 80 nanoparticles 
could achieve around 80% drug encapsulation efficiency at 
10% drug loading, which is much higher than that achieved 
by the PCL nanoparticles. The drug-loaded PCL-Tween 80 
nanoparticles showed a negative surface charge of around 
−20 mV. Compared with the PCL nanoparticles, the zeta 
potential of which is around −13.55 mV , a great increase in 
the absolute value of the zeta potential could be observed for 
the PCL-Tween 80 nanoparticles, which may result in higher 
dispersion stability. The recent literature has reported that a 
higher absolute value of the zeta potential indicates a more 
stable suspension, and a lower value indicates colloid insta-
bility, which could lead to aggregation of nanoparticles.33,34
Surface morphology
The surface morphology of the docetaxel-loaded PCL-Tween 
80 nanoparticles was investigated by field emission scanning 
electron microscopy. Figure 5 shows the field emission scan-
ning electron microscopic images for docetaxel-loaded PCL-
Tween 80 nanoparticles. Further, these images confirmed the 
particle size determined by dynamic light scattering. Analysis 
of particle morphology revealed that the PCL-Tween 80 
nanoparticles had a well defined spherical shape and were 
around 200 nm in diameter.
In vitro drug release
The in vitro drug release profiles for PCL and PCL-Tween 80 
nanoparticles in the first 28 days are presented in Figure 6. 
A biphasic release pattern of drug release was observed 
from both polymeric nanoparticles. However, the drug 
release from the PCL-Tween 80 nanoparticles was found to 
be 25.76% and 34.90% of the encapsulated drug in the first 
5 days and at 28 days, respectively, which was much faster 
than that of the PCL nanoparticles, ie, 18.25% and 24.73%, 
respectively, for the same time periods. The more rapid 
drug release from the PCL-Tween 80 nanoparticles may be 
100
0
20
W
e
i
g
h
t
 
l
o
s
s
 
(
%
)
40
60
80
100
200 300
Temperature (°C)
4005 00 600
Figure 4 Thermogravimetric profiles of PCL-Tween 80 copolymer.
Abbreviation: PCL, poly-ε-caprolactone.
Table 1 Characterization of nanoparticles (n = 3)
Sample Polymer Theoretical drug loading Size (nm) PDI ZP (mV) EE (%)
ANP PCL-Tween 80 10% 204.95 ± 3.66 0.201 ± 0.23 −20.14 ± 0.15 81.98 ± 2.61
BNP PCL-Tween 80 0 192.45 ± 1.93 0.163 ± 0.17 −18.33 ± 0.31 0
CNP PCL-Tween 80 * 217.36 ± 2.02 0.241 ± 0.09 −22.25 ± 0.29 Not shown
DNP PCL 10% 258.48 ± 5.95 0.301 ± 0.15 −13.55 ± 0.19 71.44 ± 3.61
ENP PCL * 223.33 ± 3.33 0.236 ± 0.31 −16.26 ± 0.22 Not shown
Note: *Coumarin 6.
Abbreviations: PDI, polydispersity index; ZP, zeta potential; EE, encapsulation efficiency; ANP, PCL-Tween 80 nanoparticles; DNP, docetaxel-loaded PCL nanoparticles; 
BNP, drug-free PCL-Tween 80 nanoparticles; ENP, coumarin 6-loaded PCL nanoparticles; CNP, coumarin 6-loaded PCL-Tween 80 nanoparticles.
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attributable to the lower molecular weight and higher hydro-
philicity of the PCL-Tween 80 copolymer in comparison with 
the PCL nanoparticles.
Uptake of coumarin 6-loaded 
nanoparticles by C6 cells
A C6 glioma cell line was used to investigate the uptake of 
polymeric nanoparticles by brain cancer cells. It is becoming 
clear that the therapeutic effects of drug-loaded nanoparticles 
would depend on internalization and sustained retention of 
the nanoparticles by diseased cells.18–35 Fluorescence uptake 
by C6 cells could be a useful model for assessing the in 
vitro therapeutic effect of various docetaxel   formulations 
for brain cancer. As shown in Table 1, the coumarin 
6-loaded nanoparticles used for cellular uptake research 
were highly relevant to the docetaxel-loaded nanoparticles 
in terms of their size and zeta potential. Thus, cellular uptake 
of coumarin 6-loaded PCL-Tween 80 nanoparticles and 
PCL nanoparticles was compared in this research using a 
C6 model brain cancer cell line. Uptake of coumarin 6-loaded 
nanoparticles by C6 cells was assayed following 2 hours of 
incubation, and the results are shown in Figure 7. The cellular 
nanoparticle uptake efficiency in C6 cells was found to be 
dose-dependent for both formulations. The cellular uptake 
efficiency of PCL-Tween 80 nanoparticles was 1.63-fold, 
1.76-fold, and 1.74-fold higher than that of PCL nanopar-
ticles at incubated particle concentrations of 100, 250, and 
500 µg/mL, respectively. It has been reported that the uptake 
of Tween 80-coated nanoparticles by bovine brain capillary 
cells is better than that of uncoated particles.36 Furthermore, 
it has been demonstrated that the mechanism of cellular 
uptake for biodegradable microparticles or nanoparticles is 
size-dependent.18,37 Thus, it is reasonable to expect that PCL-
Tween 80 nanoparticles would have a higher cellular uptake 
due to the Tween 80 coating and their smaller particle size.
Figure 8 shows confocal laser scanning microscopic 
images of C6 cells after 2 hours of incubation with coumarin 
6-loaded PCL-Tween 80 nanoparticles at a 200 µg/mL con-
centration. The images were obtained from the DAPI (blue) 
channel, the green fluorescent protein (green) channel, and 
the overlay of the two channels. It can be observed from 
Figure 8 that the fluorescence of the coumarin 6-loaded 
PCL-Tween 80 nanoparticles (green) is located in the 
cytoplasm around the nucleus (blue, stained by DAPI), 
Figure 5 Field emission scanning electron microscopy image of docetaxel-loaded 
PCL-Tween 80 nanoparticles.
Abbreviation: PCL, poly-ε-caprolactone.
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indicating that the nanoparticles have been internalized 
into the cells.
Assessment of nanoparticle cytotoxicity
A C6 glioma cell line was also used to investigate the cytotox-
icity of the docetaxel-loaded copolymers, which was compared 
with that for the commercial formulation, ie, Taxotere. The 
drug-loaded nanoparticles were sterilized by gamma radiation 
to exclude any sample contamination effect, and were then 
suspended and cultured with the C6 cells.   Figure 9 shows the 
viability of C6 cells after 24, 48, and 72 hours of cell culture 
with docetaxel formulated in the   PCL-Tween 80 nanoparticles 
Figure 8 Confocal laser scanning microscopy images of C6 cells after 2 hours of incubation with coumarin 6-loaded PCL-Tween 80 nanoparticles at 37.0°C. The cells were 
stained by DAPI (blue) and the coumarin 6-loaded nanoparticles are green. The cellular uptake was visualized by overlaying images obtained by green fluorescent protein 
filter and DAPI filter: left image from DAPI channel (A); center image from green fluorescent protein channel (B); right image from combined green fluorescent protein 
channel and DAPI channel (C).
Abbreviation: PCL, poly-ε-caprolactone.
0
0
20
40
C
e
l
l
 
v
i
a
b
i
l
i
t
y
 
(
%
)
60
80
100
Taxotere
ANP
DNP
51 0
Drug concentration (µg/mL)
15 20 25 0
0
20
40
C
e
l
l
 
v
i
a
b
i
l
i
t
y
 
(
%
)
60
80
100
Taxotere
ANP
DNP
*
*
51 0
Drug concentration (µg/mL)
15 20 25
0
0
20
40
C
e
l
l
 
v
i
a
b
i
l
i
t
y
 
(
%
)
60
80
100
Taxotere
ANP
DNP
*
*
51 0
Drug concentration (µg/mL)
15 20 25
A
C
B
Figure 9 Viability of C6 cells after 24 (A), 48 (B), and 72 (C) hours of cell culture with docetaxel formulated in ANP and DNP in comparison with Taxotere® at the same 
docetaxel dose.
Note: n = 6, *P , 0.05.
Abbreviations: PCL, poly-ε-caprolactone; ANP, PCL-Tween 80 nanoparticles; DNP, PCL nanoparticles.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2686
Ma et alInternational Journal of Nanomedicine 2011:6
and PCL nanoparticles, respectively, in comparison with that 
of the Taxotere formulation at the same 0.25, 2.5, 12.5, and 
25 µg/mL docetaxel dose (n = 6). It can be concluded from 
Figure 9 that both nanoparticle formulations have advan-
tages in decreasing cancer cell viability versus the current 
clinical dosage form, and that PCL-Tween 80 nanoparticles 
can have even better effects than PCL nanoparticles. For 
example, viability of C6 cells after 24 hours of incubation at 
the 12.5 µg/mL drug concentration was 77.45% for Taxotere, 
71.22% (ie, a 27.63% increase in cytotoxicity) for PCL-
Tween 80 nanoparticles, and 75.75% (ie, a 7.54% increase in 
cytotoxicity) for PCL nanoparticles.   Furthermore, compared 
with Taxotere, the cytotoxicity of C6 cells was increased 
by 64.52% (P , 0.05, n = 6) and 98.88% (P , 0.05, n = 6) 
for PCL-Tween 80 nanoparticles after 48 and 72 hours of 
i  ncubation at the 12.5 µg/mL drug concentration,   respectively. 
Such advantages of the nanoparticle formulations may have 
contributed to the effects of the Tween 80 component in 
enhancing cellular uptake of the nanoparticles. The advantage 
of cancer cell viability of the PCL-Tween 80 nanoparticles . 
PCL nanoparticles . the Taxotere formulation is dependent 
on incubation time and drug concentration. As time went 
on, both nanoparticle formulations showed   better in vitro 
  therapeutic effects in C6 cells than commercial   Taxotere. This 
may be contributed to by the controlled-release   characteristics 
of the nanoparticle formulation. For example, the   cumulative 
drug release was only 17.71%, 20.90%, and 23.33% for 
PCL-Tween 80 nanoparticles after 24, 48, and 72 hours 
(Figure 6), respectively, and the release started from 0%, 
while Taxotere immediately became 100% available for the 
C6 cells in culture.
Conclusion
A novel PCL-Tween 80 copolymer was successfully syn-
thesized in this research. PCL-Tween 80 nanoparticles were 
prepared by a modified solvent extraction/evaporation method. 
Docetaxel was chosen as the prototype anticancer drug due to 
its excellent therapeutic activity against a wide spectrum of 
cancers. The nanoparticles were found by field emission scan-
ning electron microscopy to be of spherical shape and around 
200 nm in diameter. The copolymers could encapsulate 10% of 
the drug in the nanoparticles and had released 34.9% ± 2.23% 
of the drug by 28 days. The PCL-Tween 80 nanoparticles could 
be internalized into cells and had higher cellular uptake than 
PCL nanoparticles. The drug-loaded PCL-Tween 80 nanopar-
ticles showed better in vitro cytotoxicity towards C6 glioma 
cells than commercial Taxotere at the same drug concentration. 
However, the effects of the nanoparticle formulation should 
actually be better given their controlled-release features. Fur-
ther in vivo investigations, including pharmacokinetics, biodis-
tribution, pharmacodynamics, and toxicity, will be carried out 
to evaluate the potential of these copolymer nanoparticles to 
be used as drug delivery vehicles.
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